Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Richard Klein and Alicia Jenkins.
Connection Strength

1.733
  1. Glycation does not alter LDL-induced secretion of tissue plasminogen activator and plasminogen activator inhibitor-1 from human aortic endothelial cells. Ann N Y Acad Sci. 2005 Jun; 1043:379-89.
    View in: PubMed
    Score: 0.262
  2. In vivo glycated low-density lipoprotein is not more susceptible to oxidation than nonglycated low-density lipoprotein in type 1 diabetes. Metabolism. 2004 Aug; 53(8):969-76.
    View in: PubMed
    Score: 0.247
  3. Clinical correlates of serum pigment epithelium-derived factor in type 2 diabetes patients. J Diabetes Complications. 2014 May-Jun; 28(3):353-9.
    View in: PubMed
    Score: 0.119
  4. Apolipoprotein-defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort. J Diabetes Complications. 2013 Sep-Oct; 27(5):447-53.
    View in: PubMed
    Score: 0.115
  5. LDL-containing immune complexes in the DCCT/EDIC cohort: associations with lipoprotein subclasses. J Diabetes Complications. 2011 Mar-Apr; 25(2):73-82.
    View in: PubMed
    Score: 0.093
  6. Cross-sectional associations of C-reactive protein with vascular risk factors and vascular complications in the DCCT/EDIC cohort. J Diabetes Complications. 2008 May-Jun; 22(3):153-63.
    View in: PubMed
    Score: 0.080
  7. Apolipoprotein C-III protein concentrations and gene polymorphisms in Type 1 diabetes: associations with microvascular disease complications in the DCCT/EDIC cohort. J Diabetes Complications. 2005 Jan-Feb; 19(1):18-25.
    View in: PubMed
    Score: 0.064
  8. Apolipoprotein C-III protein concentrations and gene polymorphisms in type 1 diabetes: associations with lipoprotein subclasses. Metabolism. 2004 Oct; 53(10):1296-304.
    View in: PubMed
    Score: 0.062
  9. 'Lipoproteins, glycoxidation and diabetic angiopathy'. Diabetes Metab Res Rev. 2004 Sep-Oct; 20(5):349-68.
    View in: PubMed
    Score: 0.062
  10. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci. 2004 Mar; 45(3):910-8.
    View in: PubMed
    Score: 0.060
  11. Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy. Kidney Int. 2003 Sep; 64(3):817-28.
    View in: PubMed
    Score: 0.058
  12. Fibrinogen is a marker for nephropathy and peripheral vascular disease in type 1 diabetes: studies of plasma fibrinogen and fibrinogen gene polymorphism in the DCCT/EDIC cohort. Diabetes Care. 2003 May; 26(5):1439-48.
    View in: PubMed
    Score: 0.057
  13. Serum lipoproteins in the diabetes control and complications trial/epidemiology of diabetes intervention and complications cohort: associations with gender and glycemia. Diabetes Care. 2003 Mar; 26(3):810-8.
    View in: PubMed
    Score: 0.056
  14. Pre-enrichment of modified low density lipoproteins with alpha-tocopherol mitigates adverse effects on cultured retinal capillary cells. Curr Eye Res. 1999 Aug; 19(2):137-45.
    View in: PubMed
    Score: 0.044
  15. Serum pigment epithelium-derived factor: Relationships with cardiovascular events, renal dysfunction, and mortality in the Veterans Affairs Diabetes Trial (VADT) cohort. J Diabetes Complications. 2019 10; 33(10):107410.
    View in: PubMed
    Score: 0.044
  16. Serum apolipoproteins and apolipoprotein-defined lipoprotein subclasses: a hypothesis-generating prospective study of cardiovascular events in T1D. J Lipid Res. 2019 08; 60(8):1432-1439.
    View in: PubMed
    Score: 0.043
  17. Apolipoprotein-defined lipoprotein subclasses, serum apolipoproteins, and carotid intima-media thickness in T1D. J Lipid Res. 2018 05; 59(5):872-883.
    View in: PubMed
    Score: 0.040
  18. Associations between intensive diabetes therapy and NMR-determined lipoprotein subclass profiles in type 1 diabetes. J Lipid Res. 2016 Feb; 57(2):310-7.
    View in: PubMed
    Score: 0.034
  19. Data on carotid intima-media thickness and lipoprotein subclasses in type 1 diabetes from the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC). Data Brief. 2016 Mar; 6:33-8.
    View in: PubMed
    Score: 0.034
  20. Nuclear magnetic resonance-determined lipoprotein subclasses and carotid intima-media thickness in type 1 diabetes. Atherosclerosis. 2016 Jan; 244:93-100.
    View in: PubMed
    Score: 0.034
  21. Plasma total homocysteine and carotid intima-media thickness in type 1 diabetes: a prospective study. Atherosclerosis. 2014 Sep; 236(1):188-195.
    View in: PubMed
    Score: 0.031
  22. Apolipoprotein-defined and NMR lipoprotein subclasses in the veterans affairs diabetes trial. J Diabetes Complications. 2013 Nov-Dec; 27(6):627-32.
    View in: PubMed
    Score: 0.029
  23. Risk factors related to inflammation and endothelial dysfunction in the DCCT/EDIC cohort and their relationship with nephropathy and macrovascular complications. Diabetes Care. 2008 Oct; 31(10):2006-12.
    View in: PubMed
    Score: 0.020
  24. Increased methionine sulfoxide content of apoA-I in type 1 diabetes. J Lipid Res. 2008 Apr; 49(4):847-55.
    View in: PubMed
    Score: 0.020
  25. Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care. 2004 Apr; 27(4):978-83.
    View in: PubMed
    Score: 0.015
  26. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes. 2003 Feb; 52(2):453-62.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.